List of Excipients in Branded Drug DIPROLENE AF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	DIPROLENE AF	betamethasone dipropionate	0085-0517	CARBOMER HOMOPOLYMER TYPE C
Merck Sharp & Dohme Corp	DIPROLENE AF	betamethasone dipropionate	0085-0517	CETEARETH-30
Merck Sharp & Dohme Corp	DIPROLENE AF	betamethasone dipropionate	0085-0517	CHLOROCRESOL
Merck Sharp & Dohme Corp	DIPROLENE AF	betamethasone dipropionate	0085-0517	CYCLOMETHICONE
Merck Sharp & Dohme Corp	DIPROLENE AF	betamethasone dipropionate	0085-0517	GLYCERYL OLEATE
Merck Sharp & Dohme Corp	DIPROLENE AF	betamethasone dipropionate	0085-0517	PETROLATUM
Merck Sharp & Dohme Corp	DIPROLENE AF	betamethasone dipropionate	0085-0517	PROPYLENE GLYCOL

DIPROLENE AF Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Diprolene AF is an alcohol-free topical cream containing augmented betamethasone dipropionate 0.05%, a high-potency corticosteroid used for steroid-responsive dermatoses. Its commercial value is concentrated in formulation performance rather than active-ingredient exclusivity. The main opportunity is a differentiated generic or authorized alternative that preserves corticosteroid delivery while improving tolerability, rheology, packaging, stability, or manufacturing economics.

What is Diprolene AF and how is it formulated?

Diprolene AF is a topical cream formulation of augmented betamethasone dipropionate at 0.05% strength. The product is labeled for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients aged 13 years and older. Treatment is generally limited to short durations because of the potency of the corticosteroid and the risk of local and systemic corticosteroid effects (U.S. Food and Drug Administration [FDA], 2023).

The "AF" designation refers to the alcohol-free cream presentation. This differentiates Diprolene AF from topical products that rely on ethanol or other volatile alcohols for solvent capacity, evaporation, or sensory properties.

Known excipient architecture

The FDA labeling identifies the formulation as containing the following inactive ingredients:

Component	Likely formulation role
Carbomer 934P	Gelling agent and rheology modifier
Propylene glycol	Humectant, solvent, and penetration-supporting excipient
Purified water	Continuous aqueous phase
Sodium hydroxide	Carbomer neutralization and pH adjustment

The formulation is a relatively simple aqueous gel-cream system. Carbomer provides viscosity after neutralization with sodium hydroxide. Propylene glycol supports wetting and solubilization while influencing skin hydration and drug partitioning. The absence of alcohol supports a less volatile, potentially less drying vehicle.

The active ingredient is micronized or otherwise finely dispersed augmented betamethasone dipropionate. Because the drug is poorly water soluble, particle size, dispersion quality, crystal form, and drug distribution are central to product performance.

What excipient functions determine Diprolene AF performance?

The commercial performance of Diprolene AF depends on a narrow balance between drug release, skin permeation, physical stability, and patient acceptability.

Carbomer and rheology

Carbomer controls:

• Apparent viscosity
• Yield stress
• Spreadability
• Residence time on the skin
• Drug sedimentation and redispersion
• Tube extrusion force
• Dose uniformity during application

A carbomer grade substitution can change the product’s pH response, viscosity profile, shear thinning, and interaction with the active ingredient. A generic developer cannot treat carbomer as a simple interchangeable thickener. Changes in polymer grade, neutralization level, or hydration process can alter in vitro release and in vitro permeation.

A strong formulation target is a shear-thinning cream that remains on the treatment area but spreads easily with low rubbing force. Excessive yield stress can reduce patient acceptance and increase dose variability. Insufficient structure can cause phase separation, sedimentation, and inconsistent drug distribution.

Propylene glycol

Propylene glycol has several simultaneous functions. It acts as a humectant, co-solvent, and skin-conditioning component. It can also affect the thermodynamic activity of betamethasone dipropionate and the partitioning of drug into the stratum corneum.

The excipient creates a commercial tradeoff. Higher levels may improve solubilization or delivery but can increase irritation or stinging, particularly on damaged skin. Lower levels may improve tolerability but cause changes in drug release, crystal growth, or viscosity.

A propylene-glycol-reduced formulation could have commercial appeal, but it would require comparative performance testing. Replacing propylene glycol with glycerin, polyethylene glycol, pentylene glycol, or a mixed humectant system may affect:

• Drug solubility
• Water activity
• Evaporation rate
• Preservative burden
• Skin permeation
• Sensory profile
• Microbial robustness

Sodium hydroxide and pH

Sodium hydroxide neutralizes carbomer and establishes the final pH. Small pH changes can affect viscosity and active stability. Excess neutralization may increase viscosity or alter the ionic environment. Inadequate neutralization can produce a thin product with poor suspension properties.

A generic formulation should control pH through a validated operating range rather than relying on a single target value. The relevant development variables include neutralizer concentration, order of addition, mixing shear, temperature, and hold time before filling.

Purified water and microbial control

The aqueous phase creates a microbial-control requirement. A reformulated product may need a preservative system if the reference formulation relies on the same or different microbial controls. Preservative changes can affect:

• Skin irritation
• Compatibility with the tube or closure
• Active degradation
• Carbomer viscosity
• Microbial challenge-test performance

A preservative-free version could be commercially attractive, but it would likely require a different packaging strategy, such as a metered airless pump or other low-contamination container. The product would still need to meet applicable microbial and stability requirements.

What formulation patents protect Diprolene AF?

Diprolene AF has limited contemporary exclusivity value because augmented betamethasone dipropionate is an established topical corticosteroid and the product has been marketed for decades. The core composition is unlikely to support meaningful current exclusivity on its own.

The primary commercial barriers are regulatory and technical:

1. Demonstrating pharmaceutical equivalence.
2. Matching the reference product’s physicochemical profile.
3. Demonstrating comparable topical performance.
4. Controlling active-ingredient particle size and dispersion.
5. Establishing manufacturing reproducibility.
6. Managing patent and regulatory certifications for the specific reference product.

The FDA’s Orange Book remains the controlling source for current listed patents and regulatory exclusivity. For an ANDA applicant, the relevant review is the Orange Book entry for the specific Diprolene AF reference product and strength, together with FDA patent-listing records and any applicable litigation history (FDA, 2024a).

No biosimilar pathway applies. Diprolene AF is a small-molecule topical drug, so competition proceeds through an ANDA, an authorized generic, or in some circumstances a 505(b)(2) application.

When does Diprolene AF lose exclusivity?

The product’s original small-molecule exclusivity and any early composition patents are no longer the principal barrier to generic competition. Current market entry depends on whether an applicant can obtain FDA approval and satisfy any active listed-patent certification requirements.

Exclusivity element	Commercial assessment
New chemical entity exclusivity	Expired or not applicable to current entry
Original product patent protection	Historical; unlikely to block present-day entry
Pediatric exclusivity	Must be confirmed in current FDA records
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Formulation or method-of-use patents	Must be reviewed against current Orange Book records
Generic approval pathway	ANDA is the likely route

For topical corticosteroids, old product patents often have less practical importance than the ability to reproduce the reference product’s performance. A technically non-equivalent vehicle can face regulatory delay even when patent risk is low.

What regulatory pathway applies to generic Diprolene AF?

A conventional generic would generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

Topical semisolid products are evaluated using a combination of:

• Qualitative sameness of inactive ingredients, where required
• Quantitative sameness or justified differences
• Comparative physicochemical characterization
• In vitro release testing
• In vitro permeation testing, where applicable
• Product quality and stability data
• Manufacturing process controls

FDA guidance for topical dermatological products emphasizes comparative Q1, Q2, and Q3 characterization. Q1 refers to qualitative sameness of ingredients, Q2 to quantitative sameness, and Q3 to structural and physicochemical attributes such as rheology, globule size, pH, viscosity, and microscopic characteristics (FDA, 2022).

ANDA development risks

The main regulatory risks are:

• Different carbomer grade or concentration
• Different propylene glycol level
• Drug particle-size mismatch
• Non-equivalent viscosity or yield stress
• Inadequate IVRT discrimination
• Failure to demonstrate consistent drug distribution
• Preservative incompatibility
• Tube adsorption or drug loss
• Physical instability during accelerated storage

A developer pursuing a materially different excipient system may face greater difficulty in an ANDA and could evaluate a 505(b)(2) strategy. That route may support differentiated excipients or delivery technology but carries higher development cost, greater clinical or bridging requirements, and a less predictable approval timeline.

What excipient strategies create commercial opportunities?

1. Q1/Q2-matched generic

The lowest-risk strategy is to reproduce the reference excipient system as closely as possible. This approach minimizes formulation novelty and supports an ANDA focused on comparative performance.

The commercial weakness is limited differentiation. Competition may center on price, payer contracting, supply reliability, tube size, and pharmacy distribution.

2. Propylene-glycol-optimized cream

A formulation that reduces propylene glycol while maintaining release and penetration could target patients who experience stinging or irritation. The product would need to retain the alcohol-free positioning and demonstrate comparable corticosteroid delivery.

Potential substitute systems include:

• Glycerin and polyethylene glycol combinations
• Low-irritancy glycol blends
• Encapsulated or dispersed drug particles
• Polymer-humectant systems with lower solvent activity

This strategy has stronger branding potential but carries a greater equivalence burden.

3. Preservative-free or low-preservative packaging

A preservative-free presentation could target sensitive-skin populations and dermatology practices that prefer reduced excipient exposure. The likely enabling technology would be a low-contamination pump, airless package, or unit-dose format.

Commercial benefits include a differentiated label and potential premium pricing. Costs include packaging validation, filling-line changes, device qualification, and microbial-risk management.

4. Improved sensory profile

Topical corticosteroids often compete on patient adherence. A cream that spreads rapidly, leaves less tack, and reduces visible residue could gain market share without changing the active ingredient.

Relevant development targets include:

• Lower tack after application
• Faster rub-in
• Reduced whitening
• Lower tube extrusion force
• Improved skin feel
• Stable viscosity across temperature ranges

Sensory improvement must not compromise drug uniformity or delivery.

5. Dermatology-focused packaging

Diprolene AF is used for localized inflammatory dermatoses. Packaging can support adherence and reduce waste through:

• Small-volume tubes for short-course therapy
• Metered-dose pumps
• Unit-dose sachets for samples or institutional use
• Tamper-evident closures
• Applicator-oriented packaging for difficult treatment sites

Packaging differentiation is more defensible when linked to dosing accuracy, contamination control, or improved patient use.

How does Diprolene AF compare with competing topical corticosteroids?

Product or category	Active ingredient	Relative potency	Vehicle opportunity
Diprolene AF	Augmented betamethasone dipropionate 0.05%	High	Alcohol-free aqueous cream
Betamethasone dipropionate, non-augmented	Betamethasone dipropionate	High	Cream, ointment, lotion
Clobetasol propionate	Clobetasol propionate 0.05%	Very high	Cream, ointment, foam, solution
Mometasone furoate	Mometasone furoate 0.1%	Medium to high	Cream, ointment, lotion
Triamcinolone acetonide	Triamcinolone acetonide	Medium	Broad range of vehicles

Diprolene AF competes against products with different potency, dosage forms, and prescriber preferences. A generic entrant must compete not only with other betamethasone dipropionate products but also with clobetasol, mometasone, and triamcinolone products that may have stronger distribution or lower acquisition cost.

The alcohol-free cream vehicle is most relevant where patients or prescribers prefer a nonvolatile formulation. It is less likely to command a premium in highly price-sensitive generic channels unless supported by a clear tolerability or adherence advantage.

Which companies are challenging Diprolene AF?

Competition is expected primarily from manufacturers of generic topical corticosteroids, contract manufacturers, and companies with established dermatology portfolios. The key competitor groups include:

• Generic manufacturers with topical semisolid capacity
• Dermatology-focused companies
• Authorized-generic suppliers
• Contract development and manufacturing organizations
• Specialty-pharmacy suppliers

Company-level competition should be assessed through the FDA Orange Book, Drugs@FDA approval records, FDA drug-label databases, and current National Drug Code listings. Approval status can change through product discontinuations, transfers, or new ANDA approvals, so commercial diligence should use the current FDA records rather than historical launch information.

What patent litigation and Paragraph IV risks affect entry?

A Paragraph IV certification is relevant only if the Orange Book lists an unexpired patent for the reference product. A generic applicant asserting that a listed patent is invalid, unenforceable, or not infringed may trigger litigation under the Hatch-Waxman framework.

For Diprolene AF, the practical risk profile is likely lower than for newly approved drugs because:

• The active ingredient is old.
• The product has a long marketing history.
• Core vehicle concepts are conventional.
• Any remaining patent risk would most likely involve a specific formulation, use, or manufacturing claim.

Potential litigation triggers include:

• A newly listed formulation patent
• A patent covering a specific topical vehicle
• A method-of-use patent covering a limited indication
• A claim directed to drug particle size or delivery performance
• An authorized-generic or settlement arrangement

A settlement agreement could delay entry or provide a licensed launch date. No settlement should be assumed without a documented court docket, FTC filing, SEC disclosure, or company announcement.

What manufacturing and intellectual-property barriers exist?

Manufacturing is the main barrier to a reliable generic product. Key process controls include:

1. Active wetting and deagglomeration.
2. Uniform dispersion of micronized drug.
3. Controlled carbomer hydration.
4. Consistent neutralization.
5. Temperature management.
6. Deaeration before filling.
7. Tube-fill weight control.
8. Stability monitoring for viscosity and particle growth.

The process may be difficult to replicate at commercial scale because mixing energy, vessel geometry, addition rates, and shear history affect the final microstructure. Scale-up should correlate laboratory mixing parameters with manufacturing equipment rather than relying only on ingredient quantities.

Intellectual-property opportunities are more likely to arise from improved manufacturing, packaging, or delivery systems than from the basic excipient list. Potential claim areas include:

• Reduced-particle-size distributions
• Improved drug dispersion processes
• Low-irritancy solvent systems
• Preservative-free packaging
• Enhanced stability against crystal growth
• Controlled delivery through polymer networks

What is the commercial opportunity and revenue exposure?

Diprolene AF is a mature product. Revenue exposure is therefore linked to generic substitution, payer formulary position, and supply continuity rather than exclusivity-driven price expansion.

Attractive commercial segments

• Generic substitution in retail dermatology
• Private-label dermatology products
• Authorized-generic supply
• Dermatology office dispensing
• Low-irritancy topical products
• Contract manufacturing for regional markets
• Premium packaging for adherence-sensitive patients

Revenue risks for an innovator or licensee

• Rapid price erosion after generic entry
• Therapeutic substitution to clobetasol or mometasone
• Payer preference for lower-cost corticosteroids
• Limited differentiation from conventional generic creams
• Small market opportunity for premium excipients without clinical or usability evidence

Revenue opportunities for a generic entrant

• First-to-market or early-market supply
• Reliable manufacturing during shortages
• Multi-size tube portfolio
• Institutional and dermatology-clinic contracts
• Differentiated preservative or sensory profile
• Geographic expansion through local registrations

The most defensible commercial model combines a cost-efficient Q1/Q2-matched generic with a differentiated second product based on tolerability, packaging, or sensory performance.

How strong is the Diprolene AF patent estate?

The patent estate is likely weak as a barrier to conventional generic entry but potentially relevant for narrow formulation or method claims if any remain listed or enforceable. The stronger protection resides in formulation know-how, process control, comparative performance data, and regulatory execution.

Estate component	Relative strength
Active ingredient exclusivity	Low
Basic cream composition	Low
Alcohol-free positioning	Low to moderate
Manufacturing know-how	Moderate
Particle-size and dispersion control	Moderate
Preservative-free delivery system	Moderate to high if technically novel
Method-of-use claims	Limited and indication-specific
Brand recognition	Moderate in dermatology

Key Takeaways

• Diprolene AF is an alcohol-free cream containing augmented betamethasone dipropionate 0.05%.
• Its core excipient system is based on carbomer, propylene glycol, purified water, and sodium hydroxide.
• The main development challenge is matching topical performance, not discovering a new active ingredient.
• A Q1/Q2-matched ANDA is the lowest-risk entry strategy.
• Propylene-glycol reduction, improved sensory properties, preservative-free packaging, and metered delivery offer the clearest differentiation opportunities.
• No biosimilar pathway applies.
• Current Orange Book listings must control the patent and Paragraph IV analysis for any specific reference product.
• Manufacturing reproducibility, drug dispersion, rheology, and stability are the principal technical barriers.
• The best commercial strategy is likely a low-cost generic supported by a differentiated formulation or package for higher-value dermatology channels.

FAQs About Diprolene AF Excipient and Generic Strategy

Is Diprolene AF an alcohol-free topical steroid?

Yes. Diprolene AF is the alcohol-free cream presentation of augmented betamethasone dipropionate 0.05%.

Can propylene glycol be removed from a Diprolene AF generic?

It can be evaluated, but removal may change drug solubility, release, permeation, viscosity, irritation, and stability. A formulation change requires comparative regulatory and performance support.

Is Diprolene AF eligible for a biosimilar?

No. Betamethasone dipropionate is a small-molecule active ingredient. The relevant pathways are generally an ANDA or, for a materially different product, a 505(b)(2) application.

What is the most valuable excipient innovation for Diprolene AF?

A validated low-irritancy vehicle or preservative-free package with equivalent corticosteroid delivery offers the strongest potential differentiation.

What is the principal generic-launch risk for Diprolene AF?

The principal risk is failure to reproduce the reference product’s microstructure and topical delivery profile, particularly because changes in carbomer, propylene glycol, particle size, or neutralization can affect IVRT, IVPT, and product quality.

References

1. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Draft guidance for industry. https://www.fda.gov

2. U.S. Food and Drug Administration. (2023). Diprolene AF (augmented betamethasone dipropionate) cream, 0.05%: Prescribing information. https://www.accessdata.fda.gov

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov

5. U.S. Food and Drug Administration. (2024c). Product-specific guidances for generic drug development. https://www.fda.gov